

New Jersey Prescription Opioid Drug Abuse Seminar



AGENDA

WILLIAM PATERSON UNIVERSITY
WAYNE, NEW JERSEY
SEPTEMBER 25, 2019



8:00am

Video: Impact of Opioid Abuse

Opening Remarks

Susan A. Gibson, Special Agent in Charge, Drug Enforcement Administration, New Jersey Division

Keynote Address: The Opioid Epidemic

Gurbir S. Grewal, New Jersey Attorney General

DEA Diversion Control Mission and Overview

Nancy Coffey, DEA Diversion Program Manager

9:00am - 9:30am

Drugs of Abuse and Current Trends

Luis Carrion, DEA Diversion Group Supervisor, Camden Resident Office

9:30am - 10:00am

Methods of Diversion and Effective Controls for Controlled Substances / Red Flags

Luis Carrion, DEA Diversion Group Supervisor, Camden Resident Office

10:00am - 10:15am

BREAK

10:15am - 10:45am

New Jersey State Board of Medical Examiners / Current Issues

Paul R. Rodriguez, Acting Director, New Jersey Division of Consumer Affairs

10:45am - 12:00pm

Distinguishing Drug-Seeking from Pain Relief-Seeking

Daniel P. Alford, MD, MPH, Director, Clinical Addiction Research and Education (CARE) Unit
Boston University School of Medicine | Boston Medical Center

12:00pm - 1:00pm

LUNCH

New Jersey Prescription Opioid Drug Abuse Seminar



AGENDA

WAYNE, NEW JERSEY
SEPTEMBER 25, 2019



1:00pm - 1:30pm

Health Care Fraud and Diversion

John Croes, Assistant Special Agent in Charge, US OIG-HHS, New York Regional Office

1:30pm - 2:45pm

Pain Management and Appropriate Opioid Prescribing Practices

Thomas A. Viola, R.Ph., C.C.P.

2:45pm - 3:15pm

New Jersey Prescription Drug Monitoring Program (PDMP)

Paul R. Rodriguez, Acting Director, New Jersey Division of Consumer Affairs

3:15pm - 3:30pm

BREAK

3:30pm - 4:00pm

Disposal Issues: Return of Patient Meds / Options for Patients / Take Back

Luis Carrion, DEA Diversion Group Supervisor, Camden Resident Office

4:00pm - 4:30pm

Legal Perspective on the Opioid Epidemic

Theresa M. DiGuglielmo, Esq., Frier & Levitt, LLC

4:30pm - 5:00pm

Q&A

Panel Discussion

Closing Remarks

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Federation of State Medical Boards and the United States Drug Enforcement Administration. The Federation of State Medical Boards is accredited by the ACCME to provide continuing medical education for physicians.

The Federation of State Medical Boards designates this live activity for a maximum of 7.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The New Jersey Prescription Opioid Drug Abuse Seminar is not funded by any commercial entity. DEA's participation in this event as a co-sponsor does not constitute an endorsement by the DEA of FSMB or their products or services.